The spread of sexually transmitted infections caused by herpes simplex virus type 2 (HSV-2) has continued unabated. At least 20% of the United States population has been infected with HSV-2 and there is a high probability of further virus transmission by asymptomatic carriers. Given the absence of effective vaccines, this indicates the need to develop prophylactic measures such as topical microbicides that have antiviral activity. Recent studies indicate that cellulose acetate phthalate (CAP), an inactive pharmaceutical excipient commonly used in the production of enteric tablets and capsules, is a broad specificity microbicide against diverse sexually transmitted pathogens. When appropriately formulated in micronized form, it inactivates various viruses, including HSV-2, in vitro. Here we show that CAP inhibits HSV-2 infection in the mouse model of genital HSV-2 infection. Pretreatment with micronized CAP formulated in a glycerol-based cream with colloidal silicone dioxide significantly reduced the proportion of HSV-2-infected mice (10% virus shedding, 0-5% lesion development and 0% fatality for CAP as compared to 84% shedding, 63% lesion development and 63% fatality in saline-treated mice). These differences were significant (P≤0.0002 by the test of equality of two proportions). Virus titres in the minority of mice that developed infection were similar to those in untreated mice. HSV-2 infection was not inhibited by treatment with CAP formulated with other inactive ingredients (for example povidone plus crosprovidone) instead of silicone dioxide, presumably reflecting CAP complexation/inactivation. These data suggest that properly formulated, CAP may be an efficacious agent for preventing vaginal transmission of genital herpesvirus infections.
The spread of sexually transmitted diseases (STDs) continues unabated despite educational efforts made in response to the human immunodeficiency virus (HIV) epidemic. Recent studies indicate that at least 20% of people in the United States have been infected with sexually transmitted herpes simplex virus type 2 (HSV-2) (Arvin & Prober, 1997; Fleming et al., 1997) , and that the prevalence is even higher in some developing countries (Nahmias et al., 1990) . In addition to recurrent genital lesions, the virus occasionally causes severe neurological or systemic disease, a potentially lethal disease in the neonate and it increases the risk of human immunodeficiency virus (HIV) infection and severity of disease symptoms (Aurelian, 1990; Feng et al., 1996; Posavad et al., 1997) . In patients with immunological deficiencies, including those resulting from infection with HIV, HSV-2 infections can cause severe hyperproliferative lesions that are difficult to treat (Tong & Mutasim, 1996; Beasley et al., 1997) . HSV-2 is also a transforming virus and causes tumours in infected animals (reviewed in Aurelian et al., 1995; Di Luca et al., 1995) . Although the infection can be treated with antiviral drugs, effective longterm suppression of recurrent genital lesions is still problematic. There is also a very high probability that virus is further spread by untreated people and asymptomatic carriers that are not receiving antiviral therapy (Aurelian & Kessler, 1985; Mertz, 1993) .
With the absence of successful vaccines capable of preventing HSV-2 infections, the possibility that antiviral chemotherapy will have a major impact on HSV-2 prevalence (White & Garnett, 1999) and the failure of programmes to increase the use of condoms underscore the need for preventive use of a vaginal topical antiviral agent.
Introduction
Agents such as sulphated polysaccharides (Baba et al., 1988) have shown activity against HSV infection in vitro by inhibiting virus binding/internalization to target cells, but their in vivo activity is relatively poorly understood. It therefore seemed that the fastest way to introduce topical microbicides into practice was the application of over-thecounter contraceptives containing the detergent nonoxynol-9 (N-9), which inactivates HSV-2 as well as HIV ( Jennings & Clegg, 1993) and Chlamydia trachomatis (Lyons & Ito, 1995) in vitro. N-9 was also shown to protect from genital HSV infection in animal models (Whaley et al., 1993; Zeitlin et al., 1997) . However, repeated use of N-9 was found to cause adverse effects and irritations which may increase susceptibility to STD infections, particularly HIV (Whaley et al., 1993; Zeitlin et al., 1997; Kilmarx et al., 1998; Stafford et al., 1998) . Chemical modification of the bovine protein β-lactoglobulin (β-LG) by 3-hydroxyphthalic anhydride resulted in the generation of an agent (3HP-β-LG) with in vitro activity against both HSV-2 and HSV-1 . 3HP-β-LG was shown to inhibit HSV-2 infection in the mouse vaginal model, indicating that it may fulfil critical requirements for an effective prophylactic agent with antiherpetic activity (Kokuba et al., 1998) . However, the disadvantage of this compound has been the lack of activity against bacterial STD pathogens (unpublished results of studies done for AR Neurath under contract with SRA Life Sciences, Falls Church, Va., USA). Accordingly, a broad-spectrum formulation was recently developed, which consists of pharmaceutical excipients with established safety records and this has been shown to inhibit HSV-2 growth in vitro (Neurath et al., 1999) . Here we report that this formulation also inhibits infection with HSV-2 in the mouse vaginal model.
Materials and Methods

Cells and virus
African green monkey cells (Vero) were obtained from ATCC and cultured in Eagle's minimal essential medium (MEM) supplemented with 10% foetal calf serum (FCS). The cells were used for virus production, as previously described (Aurelian, 1992) . Human embryonic lung cells (MRC-5) were purchased from Flow Laboratories. They were maintained and passaged in MEM-10% FCS with 0.02 M HEPES (N-2-hydroxyethyl-piperazine-N′-ethanesulphonic acid) buffer, 2 mM L-glutamine and antibiotics [penicillin (100 U/ml) and streptomycin (0.1 mg/ml)] and used for virus isolation (Aurelian, 1992) . The HSV-2 G strain was isolated from genital lesions (Ejercito et al., 1968) and became a standard laboratory strain. The stock used in these experiments underwent limited in vitro passage (20 passages). It is highly virulent, causing mortality in 50% of intravaginally infected mice (IC 50 ) at 1×10 5 p.f.u. It was used as previously described by Kokuba et al. (1998) .
Plaque assay
Confluent monolayers of Vero cells in six-well Costar microplates (Bellco Glass, Vineland, N.J., USA) were infected with serial dilutions of the virus inoculum. After 2 h adsorption at 37°C the virus inoculum was aspirated and replaced with MEM supplemented with 1% FCS and 0.3% pooled human γ-globulin. Plates were incubated at 37°C for 48 h, at which time the cells were fixed with methanol and stained with 10% Giemsa. After the plates were aspirated and dried, plaques were counted at 13× magnification. Results are expressed as p.f.u./ml (Aurelian, 1992).
Antiviral compound
CAP was formulated as previously described by Neurath et al. (1999) in order to avoid the following problems: (i) low solubility in aqueous solutions at pH <6 (Wade & Weller, 1994) ; (ii) hydrolysis at room temperature during storage in aqueous solutions; and (iii) solubility in several biocompatible organic solvents followed by precipitation out of solution upon contact with aqueous solvents (AR Neurath, unpublished results). Specifically, a preparation of micronized CAP [Aquateric containing 66-73% CAP, a polyoxyethylene-polyoxypropylene block copolymer and distilled acetylated monoglycerides, used in aqueous media as an enteric film-coating liquid (15.9 g) (FMC, Philadelphia, Pa., USA)] was mixed with glycerol (70.2 g).
In formulation 1, polyvinylpyrrolidone K-30 (Spectrum Quality Products, New Brunswick N.J., USA) (11.1 g) and crospovidone NF (ISP Technologies, Wayne, N.J., USA) (2.8 g) were added in order to maintain the micronized CAP in suspension. In formulation 2, polyvinylpyrrolidone plus crospovidone were replaced with colloidal silicone dioxide M-5P (Cabot, Cab-O-Sil Division, Tuscola, Ill., USA), an excipient with an established use in vaginal preparations (Wade & Weller, 1994) . This formulation contained 23.7 g Aquateric and 7.89 g silica per 100 g glycerol. All components of these formulations were USP grade and have been approved for human medicinal use (Wade & Weller, 1994) .
Animal studies
We used a modification of the mouse vaginal model of HSV-2 infection (Walz et al., 1977; Richards et al., 1981; Smee et al., 1983; Whaley et al., 1993) adapted to mimic human sexually transmitted HSV-2 infections, as previously described (Kokuba et al., 1998) . Briefly, SwissWebster female mice (Hilltop Laboratories, Chatsworth, Calif., USA) weighing approximately 20 g each, were anaesthetized (Metafane, Pitman-Moore, Mundelein, Ill., USA) and the vaginas were extensively lavaged by three cycles of exposure to 15 µl saline. A solution containing HSV-2 was prepared in MEM and 5 µl (2×10 5 p.f.u.) was delivered. The pipette was moved in and out four times and the cervix was abraded with the tip of the pipette, a procedure needed for reproducible infection. Treatment was with CAP in formulations 1 or 2, formulations 1 or 2 lacking CAP (diluted 1:5 or 1:20 in saline) or saline. Treatment consisted of 10 µl administered immediately before infection. Animals were examined for lesion development daily for 10 days (or until death). The severity of the HSV lesions was expressed as an arbitrary lesion score in which two represents vulvovaginal swelling, three represents swelling with high exudation and redness and four also includes erosion of the vaginal mucosa which extends over the perineo-vulvar portion. To measure virus shedding, vaginas were lavaged with 10 µl of collection medium consisting of MEM with 0.8% BSA, 8 mM HEPES buffer and antibiotics [amphotericin B (4 µg/ml), penicillin (400 U/ml) and streptomycin (0.4 mg/ml)]. The sample was diluted in 500 µl of inoculation medium (MEM, 0.45% BSA, 18 mM HEPES buffer, 4.5 µg/ml amphotericin B, 91 U/ml penicillin and 91 µg/ml streptomycin) and placed on MRC-5 cells. After 12 h of incubation at 37°C on a rotary shaker, the inoculum was removed and replaced with growth medium (MEM-10% FCS, 2 mM L-glutamine and antibiotics) for virus isolation (Aurelian, 1992) . In some experiments, samples were serially diluted and assayed for virus titres by plaque assays.
Results
As summarized in Tables 1 and 2 , the vaginal HSV-2 model used in these experiments is reproducible, with an incidence of infection in untreated animals virtually identical to that reported before (Kokuba et al., 1998) . Thus, virus was first isolated from untreated mice infected with 2×10 5 p.f.u of HSV-2 at 3 days post-infection (p.i). The proportion of animals shedding virus increased with time p.i. reaching maximum levels on day 5 p.i., concomitant with the appearance of genital lesions that consisted of vulvovaginal swelling, high exudation and redness (score=3).
In rare animals, lesions first presented without exudation (score=2) and increased in severity within 24 h. Some mice also exhibited erosion of the vaginal mucosa which extended over the perineo-vulvar portion (score=4). Lesion severity was maintained throughout follow-up and was similar in all groups, including the small number of CAP-treated mice that developed lesions. Virus titres in vaginal specimens obtained at 5 days p.i. ranged between 3×10 5 to 2×10 7 p.f.u. The effectiveness of a putative microbicide is best observed when animals are treated shortly before infection (Kokuba et al., 1998) , therefore all experiments in these series used the pretreatment protocol. In the first series, mice were treated with 10 µl of CAP in formulation 2 (colloidal silicone dioxide M-5P), formulation 2 alone (vehicle) or saline at 10-30 min before infection with 2×10 5 p.f.u of HSV-2. To allow for a more accurate definition of the amount of delivered formulation, the consistency of the formulation (with or without CAP) was decreased by dilution (1:5 or 1:20 in saline) prior to use. As summarized in Table 1 , virus was isolated from 36/43 (84%) of the mice given saline and 27 of these [27/43 (63%)] developed genital lesions and died. Death occurred on days 7-9 p.i. This compares to virus isolation from 2/19 (11%) and 1/10 (10%) of mice given CAP at a 1:5 and 1:20 dilution, respectively. Animals treated with CAP developed lesions during the 10 days of follow-up only if they were positive for virus shedding. Virtually all CAP-treated mice survived infection (Table 1) . These isolation/disease levels were significantly different from those in the saline group (P<0.0001 for virus shedding, lesion development and fatality by the test of equality of two proportions) and the Antiviral activity of CAP in the mouse model of HSV-2 Virus titres in the minority of animals that became infected after treatment with CAP were not decreased, suggesting that treatment interferes with initial infection rather than virus replication. Indeed, the titres of virus isolated from the untreated mice ranged between 3×10 5 to 2×10 7 p.f.u./ml with a mean titre of 2×10 6 p.f.u./ml. Essentially similar titres were seen in the animals treated with formulation 2 without CAP [2×10 5 to 6.4×10 6 (mean 2×10 6 p.f.u./ml)] or with CAP [1×10 6 to 2.8×10 6 (mean 1.5×10 6 p.f.u./ml)]. In vitro, CAP has antiviral activity also when prepared in another formulation (formulation 1) (Neurath et al., 1999) . To examine whether this is also true in vivo, a separate series of experiments was carried out using the same protocol but with CAP prepared with formulation 1 (polyvinylpyrrolidone K-30 plus crospovidone NF). As summarized in Table 2 , virus was isolated from 20/21 (95%) of the animals given saline, 15/18 (83%) of those given formulation 1 alone and 15/19 (79%) of those given CAP in formulation 1. Lesions developed in 18/21 (86%) of the mice given saline and all of them died. A similar proportion of mice given formulation 1 without CAP developed lesions and died [16/19 (84%) ]. This compares to 13/19 (68%) of mice developing lesions and dying when treatment was with CAP, a minimal difference from the other two groups.
Statistical analysis of the data in Tables 1 and 2 used the test of equality of two proportions to compare CAP treated animals to those treated with saline or formulation alone (vehicle). Significant differences were seen between the CAP (diluted 1:5 or 1:20) and the saline groups in the case of formulation 2 (P<0.0001 for virus shedding, lesion development or fatality). The groups treated with CAP in formulation 2 were also significantly different from those treated with formulation 2 alone (P<0.001, P<0.0084 and P<0.0017 for virus shedding, lesion development and fatality, respectively) in CAP (1:5 dilution) versus formulation 2 (1:5 dilution) groups. By contrast, when delivered in formulation 1, the antiviral activity of CAP was minimal and there were no statistically significant differences between this group and the control groups in terms of virus shedding, lesion development or death. Minimal antiviral activity was also evident for formulation 2 without CAP (vehicle) (P<0.01 for virus shedding, lesion development or fatality relative to saline group).
Discussion
Efficacious topical microbicides are expected to be used repeatedly over decades. Accordingly, they should have an established safety record and should preferably not be spread systemically after topical application. They should: (i) be inexpensive; (ii) be produced from widely available resources; (iii) have a broad activity spectrum; and (iv) inactivate the infectivity of the respective STD pathogens. CAP appears to meet these criteria. It is commonly used as an enteric film coating material or as a matrix binder for tablets or capsules. Its safety has been extensively studied and it has been shown to be free of adverse effects. Vaginal irritation tests in the rabbit model further confirmed safety (unpublished results of study done for AR Neurath under contract with Bioqual, Rockville, Md., USA). CAP is a high molecular weight compound (approximately 60 kDa), suggesting that, if topically applied, it will not spread systemically. The likelihood of CAP spreading beyond the site of application has been further decreased by use in a micronized, rather than soluble form. In vitro CAP has antiviral activity against human cytomegalovirus, HSV-1, HSV-2 and HIV as well as exhibiting antimicrobial activity against C. trachomatis, Trichomonas vaginalis, Neisseria gonorrhea and Hemophilus ducrey (Neurath et al., 1999) . However, antiviral activity in vivo is still unclear.
The salient feature of the data presented in this report is the observation that appropriately formulated CAP (in col- (68) *Mice were infected with HSV-2 (2×10 5 p.f.u.) in the presence of CAP prepared in formulation 1 diluted 1:5 in saline. Similar dilutions of formulation 1 or saline were used as controls. Virus shedding was determined on day 5 p.i. Visible lesions developed on day 5 p.i. Death was on days 7-9 p.i.
loidal silicone dioxide) prevents HSV-2 infection in mice, a finding consistent with its antiviral activity in vitro (Neurath et al., 1999) . The following comments seem pertinent with respect to these findings.
Our model attempted to reproduce the conditions of infection in humans. Infection was not preceded by any treatment that may alter infectivity. Virus delivery mimicked coitus and included mucosal abrasion, a potential coitus-related complication that increases the likelihood of infection. The model is reproducible, as evidenced by the levels of infection in untreated animals, which were virtually identical to those reported before (Kokuba et al., 1998) . The kinetics of virus shedding and lesion development were also similar to those previously described (Kokuba et al., 1998) .
We found that pretreatment with CAP (formulation 2) reduced the proportion of infected animals, as evidenced by a significant decrease in the incidence of virus shedding, a lower proportion of animals with herpetic lesions and a significant reduction in death resulting from severe infection. As indicated by the small number of treated animals that developed disease, the severity of the lesions was not altered by CAP treatment, suggesting that CAP functions prophylactically. Protective activity was observed even at a 1:20 dilution, indicative of the effectiveness of this formulation as a potential topical microbicide. Virus shedding was also reduced by treatment with formulation 2 alone (albeit to a lower extent) and we conclude that ingredients other than CAP present in this formulation contribute to antiviral activity. From the practical standpoint of developing an effective broad-spectrum microbicide, this is a potentially desirable development. However, significant differences between treated and untreated animals were primarily seen with CAP, suggesting that it provides the bulk of the antiviral activity.
The difference between the two formulations in effectiveness of preventing HSV-2 infection is striking. It is also a reminder that 'inactive' ingredients in a formulation can dramatically affect the biological activity of the active ingredient in vivo, although such distinctions could not be predicted from the results of in vitro experiments (Neurath et al., 1999) . The two formulations differ with respect to components added to maintain the uniformity of the formulation and to prevent the micronized CAP from separating out from the bulk of the glycerol-based creams. Povidone plus crospovidone were added to formulation 1; colloidal silicone dioxide to formulation 2. Povidone and crospovidone preparations were reported to form chemical complexes with many substances, including pharmacologically active compounds. Many of these compounds, including several synthetic polymers, have carboxylic acid residues (Plaizier-Vercammen & De Neve, 1980; Iliopoulos et al., 1987; Leiva et al., 1994; Buhler, 1996) . The complex formation between povidone and these compounds occurs mostly through hydrogen bonds. It seems likely that CAP, being a polycarboxylic acid polymer, forms a complex with povidone as does polyacrylic acid, another polycarboxylic polymer (Iliopoulos et al., 1987) . Indeed, such complex formation was confirmed experimentally. Thus, soluble povidone is bound to insoluble micronized CAP causing its partial solubilization, followed by enhanced hydrolysis of the ester bond between phthalic acid and the cellulose polymer backbone (AR Neurath & N Strick, unpublished results) . This indicates that the phthalic acid residues are essential for antiviral activity, probably by providing a low pH buffering system and hydrophobicity, mimicking the effect of detergents without being soluble in the vaginal environment. Thus, when properly formulated, topically applied CAP caused a significant decrease in HSV-2 infection/disease in vivo, suggesting that it may prevent sexual transmission of HSV-2. The CAP formulations also proved to be promising in the SIV/monkey model for vaginal infection (unpublished results of studies done for AR Neurath under contract with Primedica, Woucester, Mass., USA).
